title: Anti-analgesic effect of the mu/delta opioid receptor heteromer revealed by ligand-biased antagonism.
abstract: Delta (DOR) and mu opioid receptors (MOR) can complex as heteromers, conferring functional properties in agonist binding, signaling and trafficking that can differ markedly from their homomeric counterparts. Because of these differences, DOR/MOR heteromers may be a novel therapeutic target in the treatment of pain. However, there are currently no ligands selective for DOR/MOR heteromers, and, consequently, their role in nociception remains unknown. In this study, we used a pharmacological opioid cocktail that selectively activates and stabilizes the DOR/MOR heteromer at the cell surface by blocking its endocytosis to assess its role in antinociception. We found that mice treated chronically with this drug cocktail showed a significant right shift in the ED50 for opioid-mediated analgesia, while mice treated with a drug that promotes degradation of the heteromer did not. Furthermore, promoting degradation of the DOR/MOR heteromer after the right shift in the ED50 had occurred, or blocking signal transduction from the stabilized DOR/MOR heteromer, shifted the ED50 for analgesia back to the left. Taken together, these data suggest an anti-analgesic role for the DOR/MOR heteromer in pain. In conclusion, antagonists selective for DOR/MOR heteromer could provide an avenue for alleviating reduced analgesic response during chronic pain treatment.
authors.affiliation: Ernest Gallo Clinic and Research Center, University of California San Francisco, Emeryville, California, USA.
authors.forename: Laura
authors.initials: L
authors.lastname: Milan-Lobo
authors.forename: Johan
authors.initials: J
authors.lastname: Enquist
authors.forename: Richard M
authors.initials: RM
authors.lastname: van Rijn
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Whistler
mesh_terms: D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D004305:Dose-Response Relationship, Drug; D057809:HEK293 Cells; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D010146:Pain / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D059408:Pain Management; D055503:Protein Multimerization; D055550:Protein Stability / Q000187:drug effects; D017465:Receptors, Opioid, delta / Q000235:genetics / Q000378:metabolism*; D017450:Receptors, Opioid, mu / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics
chemical_list: D000701:Analgesics, Opioid; D017465:Receptors, Opioid, delta; D017450:Receptors, Opioid, mu
references.citation: Curr Opin Pharmacol. 2005 Feb;5(1):60-8
references.pmid: 15661627
references.citation: Cell. 2009 Jun 12;137(6):1148-59
references.pmid: 19524516
references.citation: Eur J Pharmacol. 1995 Nov 3;286(1):105-8
references.pmid: 8566146
references.citation: Biochemistry. 2007 Nov 13;46(45):12997-3009
references.pmid: 17941650
references.citation: Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13117-22
references.pmid: 20615975
references.citation: Nature. 2000 Dec 7;408(6813):720-3
references.pmid: 11130073
references.citation: Eur J Pharmacol. 2007 Apr 10;560(2-3):132-41
references.pmid: 17307158
references.citation: J Pharmacol Exp Ther. 2003 Dec;307(3):1054-64
references.pmid: 14557380
references.citation: J Pharmacol Exp Ther. 2011 Jun;337(3):868-75
references.pmid: 21422164
references.citation: FASEB J. 2007 Aug;21(10):2455-65
references.pmid: 17384143
references.citation: J Neurosci. 2000 Nov 15;20(22):RC110
references.pmid: 11069979
references.citation: Mol Pharmacol. 1994 Feb;45(2):330-4
references.pmid: 8114680
references.citation: Curr Biol. 2008 Jan 22;18(2):129-35
references.pmid: 18207746
references.citation: Mol Pharmacol. 2008 Oct;74(4):972-9
references.pmid: 18612077
references.citation: Mol Pharmacol. 2011 Jun;79(6):1044-52
references.pmid: 21415307
references.citation: Neuron. 2001 Dec 6;32(5):829-39
references.pmid: 11738029
references.citation: Trends Pharmacol Sci. 2007 Jan;28(1):23-31
references.pmid: 17150262
references.citation: J Pain Symptom Manage. 2009 Apr;37(4):632-41
references.pmid: 19345298
references.citation: Brain Res Bull. 1996;39(3):185-8
references.pmid: 8866695
references.citation: Mol Pain. 2007 Dec 04;3:37
references.pmid: 18053223
references.citation: Trends Pharmacol Sci. 2001 Nov;22(11):560-4
references.pmid: 11698099
references.citation: Psychopharmacology (Berl). 2002 Oct;163(3-4):420-9
references.pmid: 12373443
references.citation: Nature. 2012 Mar 21;485(7398):321-6
references.pmid: 22437502
references.citation: J Pharmacol Exp Ther. 1997 Jun;281(3):1350-6
references.pmid: 9190871
references.citation: Mol Pharmacol. 1998 Mar;53(3):377-84
references.pmid: 9495801
references.citation: J Biol Chem. 2005 Nov 18;280(46):38478-88
references.pmid: 16159882
references.citation: Br J Pharmacol. 2007 Jul;151(6):877-87
references.pmid: 17502848
references.citation: Proc Natl Acad Sci U S A. 2005 Jun 21;102(25):9050-5
references.pmid: 15932946
references.citation: J Clin Oncol. 2001 Jun 1;19(11):2898-904
references.pmid: 11387363
references.citation: Neuron. 1999 Sep;24(1):243-52
references.pmid: 10677041
references.citation: J Pharmacol Exp Ther. 1991 Jul 1;258(1):299-303
references.pmid: 1649297
references.citation: Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19208-13
references.pmid: 16365317
references.citation: Neuropharmacology. 2011 Jan;60(1):58-65
references.pmid: 20713067
references.citation: Curr Biol. 2005 Jun 7;15(11):1028-33
references.pmid: 15936273
references.citation: Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):5135-9
references.pmid: 15044695
references.citation: J Neurosci. 2010 Mar 31;30(13):4735-45
references.pmid: 20357124
references.citation: J Biol Chem. 2000 Aug 25;275(34):26128-35
references.pmid: 10842167
references.citation: Neuron. 2011 Jan 13;69(1):120-31
references.pmid: 21220103
references.citation: Br J Pharmacol. 2010 Nov;161(5):1122-36
references.pmid: 20977461
references.citation: Sci Signal. 2010 Jul 20;3(131):ra54
references.pmid: 20647592